SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconus
The Switzerland Eye Research Institute has announced that the breakthrough transepithelial riboflavin formulation known as ParaCel, and based on the research of its CEO and Founder Roberto Pinelli, MD, has been selected among many others by the FDA for an epithelium-on corneal collagen cross-linking protocol for patients with progressive keratoconus, according to a press release.
All of the intellectual property rights to produce, market and distribute ParaCel have been acquired by AVEDRO, Inc. Waltham. Mass. in 2011. Avedro reached the agreement with FDA in order for many patients and practices in the US to offer a new procedure designed to eliminate the need to remove the epithelium, explained Avedro’s chief medical officer Rajesh K. Rajpal, MD, in the release.
“ParaCel has been formulated to softly penetrate the corneal epithelium without the need to remove it. The higher concentration of riboflavin and proprietary formulation allow for the fastest penetration and diffusion into the corneal stroma. The osmotic property of this distinctive riboflavin solution is the key to the efficacy and safety of this treatment. I am happy to know that the molecule I conceived and then released to AVEDRO was chosen by such an outstanding institution as the FDA”, said Dr. Roberto Pinelli.
ABOUT SWITZERLAND EYE RESEARCH INSTITUTE
Founded by Dr. Pinelli in 2013, the Switzerland Eye Research Institute (SERI Lugano) is a private center based in Lugano, Switzerland, specializing in the diagnosis, study and treatment of visual defects and eye diseases. Dr. Pinelli has performed more than 20,000 procedures over the last 20 years. His expertise in the treatment of keratoconus led to his personal technique for a transepithelial osmotic accelerated cross-linking for keratoconus with the use of ParaCel riboflavin and to the introduction of cross-linking in the refractive procedures performed at the Institute on a regular basis.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AROMA-BIT23.7.2019 03:32:07 CEST | Press release
Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size
CA-LOGITECH23.7.2019 03:02:05 CEST | Press release
Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth
CA-GILEAD-SCIENCES22.7.2019 18:02:07 CEST | Press release
Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance
IBC22.7.2019 17:38:06 CEST | Press release
IBC Celebrates Young Talent in the Industry
CA-GILEAD-SCIENCES,-INC.22.7.2019 17:02:04 CEST | Press release
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV
PACIFIC-DRILLING-S.A.22.7.2019 15:44:09 CEST | Press release
Pacific Drilling Appoints James W. Harris as Chief Financial Officer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom